Merck (WBO:MRK) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:MRK Merck & Co Inc WBO:MRK
67 GF Score
Price €127.66
GF Value €105.84
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck  (WBO:MRK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Merck Cyclically Adjusted PB Ratio Related Terms


Merck Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted PB Ratio Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.97 7.18 6.72 6.41 6.01

Merck Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.37 4.47 5.89 6.71 7.19

WBO:MRK vs ABBV, AMGN, GILD: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PB Ratio falls into.


WBO:MRK
67GF Score
Merck & Co Inc WBO:MRK
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Merck's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Merck's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.875/333.9520*333.9520
=14.875

Current CPI (Jun. 2026) = 333.9520.

Merck Quarterly Data

Book Value per Share CPI Adj_Book
201609 14.163 241.428 19.591
201612 13.903 241.432 19.231
201703 13.677 243.801 18.734
201706 12.767 244.955 17.406
201709 11.945 246.819 16.162
201712 10.676 246.524 14.462
201803 10.238 249.554 13.700
201806 10.511 251.989 13.930
201809 10.575 252.439 13.990
201812 9.070 251.233 12.056
201903 9.540 254.202 12.533
201906 9.489 256.143 12.371
201909 9.682 256.759 12.593
201912 9.123 256.974 11.856
202003 9.496 258.115 12.286
202006 9.767 257.797 12.652
202009 9.867 260.280 12.660
202012 8.206 260.474 10.521
202103 9.089 264.877 11.459
202106 11.116 271.696 13.663
202109 12.254 274.310 14.918
202112 13.310 278.802 15.943
202203 14.557 287.504 16.909
202206 16.357 296.311 18.435
202209 17.940 296.808 20.185
202212 17.005 296.797 19.134
202303 17.014 301.836 18.824
202306 13.984 305.109 15.306
202309 15.386 307.789 16.694
202312 13.458 306.746 14.652
202403 14.779 312.332 15.802
202406 16.061 314.175 17.072
202409 15.769 315.301 16.702
202412 17.717 315.605 18.747
202503 17.808 319.799 18.596
202506 16.697 322.561 17.287
202509 17.760 324.800 18.260
202512 18.120 324.054 18.673
202603 16.141 330.213 16.324
202606 14.875 333.952 14.875

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Merck (WBO:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of €127.66 is trading 20.6% above its estimated GF Value™ of €105.84. GuruFocus considers Merck to be Modestly Overvalued.

Key valuation signals for WBO:MRK:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €105.84 vs. price of €127.66 (20.6% above fair value)
  • GF Score™: 67/100 with 8 warning signs

No single metric tells the full story. See the WBO:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
67GF Score

Get the complete analysis for WBO:MRK

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€127.66
Price
€105.84
GF Value